Pharvaris N.V. PHVS
Set alert
33.53 USD -0.05 -0.15%
At close · Oct 30
34.00 +0.47 +1.40%
After hours · Oct 30, 4:25 PM ET
33.10 Day range 33.94
21.59 52-week range 38.86
- YTD
- +20.83%
- 1 year
- +50.76%
- Open
- 33.48
- Prev close
- 33.58
- Mkt cap
- 2.35B
- Vol
- 1.48M
- Avg vol
- 786.85K
- EPS
- -3.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 33.10
- High
- 33.94
- Forward P/E
- -10.97
- Beta
- -2.46
- Short ratio
- 3.40
- Inst. own
- 93.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 33.72
- 200-d avg
- 30.96
- 1y target
- 57.52
1Y chart
Events in this range
- Nov 12, 2025Earnings: -0.7; estimate -0.78; surprise 10.26%
- Apr 2, 2026Earnings: -0.84565; estimate -0.71462; surprise -18.34%
- May 12, 2026Earnings: -0.7; estimate -0.82187; surprise 14.83%
- Aug 12, 2026Earnings: -0.81; estimate -0.7467; surprise -8.48%
- Sep 9, 2026Rating: RBC Capital · Outperform → Outperform
- Sep 9, 2026Rating: Wells Fargo · Overweight → Overweight
- Sep 9, 2026Rating: Leerink Partners · Outperform → Outperform
- Sep 9, 2026Rating: Morgan Stanley · Overweight → Overweight
- Sep 10, 2026Rating: Guggenheim · Buy → Buy
- Oct 23, 2026Rating: B of A Securities · Neutral → Buy
Signals (54)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 5, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 7, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 6, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 29, 2026 | 6 months ago |
| SMA: Bullish | Apr 24, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Mar 26, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 26, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 11, 2026 | 7 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 4, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 21, 2026 | 9 months ago |
| SMA: Bullish | Jan 20, 2026 | 9 months ago |
| SMA: Bearish | Jan 16, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 6, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 23, 2025 | 10 months ago |
| SMA: Bullish | Dec 11, 2025 | 10 months ago |
| SMA: Bearish | Dec 10, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 9, 2025 | 10 months ago |
| RSI: Overbought | Nov 28, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 11, 2025 | 11 months ago |
Key statistics
- Market cap
- 2.35B
- Enterprise value
- 2.04B
- Trailing P/E
- 0.00
- Forward P/E
- -10.97
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 6.97
- EPS (TTM)
- -3.06
- Beta
- -2.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -90.36M
- Total cash
- 318.28M
- Total debt
- 673.73K
- Return on equity
- -70.46%
- Shares outstanding
- 70.20M
- Short % of float
- 4.26%
- 50-day average
- 33.72
- 200-day average
- 30.96
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 57.52 +71.5% upside
Now 33.53
- Target (low)
- 40.91
- Target (mean)
- 57.52
- Target (high)
- 78.82
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.71909.
Financials — quick view
PHVS Revenue — quarterly 0
PHVS Net income — quarterly -47.84M
PHVS EPS — quarterly -0.70
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.81867 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.7467 | -0.81 | -0.06 | -8.48% |
| May 12, 2026 | Mar 31, 2026 | -0.82187 | -0.70 | +0.12 | +14.83% |
| Apr 2, 2026 | Dec 31, 2025 | -0.71462 | -0.84565 | -0.13 | -18.34% |
| Nov 12, 2025 | Sep 30, 2025 | -0.78 | -0.70 | +0.08 | +10.26% |
| Aug 12, 2025 | Jun 30, 2025 | -0.87 | -0.94 | -0.07 | -8.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2026 | B of A Securities | up | Neutral | Buy |
| Sep 10, 2026 | Guggenheim | main | Buy | Buy |
| Sep 9, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 9, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 9, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 9, 2026 | RBC Capital | main | Outperform | Outperform |
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- pharvaris.com
News
- This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
- This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
- Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
- This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday
- This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
- Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
- This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
- B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review
Your note
Sign in to keep a note on PHVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABELE STEFAN | Chief Operating Officer | Sale | Sep 14, 2026 | 39,068 |
| BJORK ELISABETH | Director | Sale | Sep 16, 2026 | 15,167 |
| GLASSMAN ROBERT R. | Director | Sale | Sep 16, 2026 | 10,500 |
| LESAGE ANNE SIMONNE J PH.D. | Officer | Sale | Sep 16, 2026 | 0 |
| LU PENG | President | Conversion of Exercise of derivative security | Sep 21, 2026 | 110,261 |
| MODIG BERNDT B.A.E | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 16, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.04% | 6,565,272 | 220.13M | Jun 29, 2026 |
| General Atlantic, L.P. | 10.02% | 6,550,757 | 219.65M | Jun 29, 2026 |
| Foresite Capital Management IV, LLC | 7.31% | 4,778,581 | 160.23M | Jun 29, 2026 |
| venBio Partners LLC | 7.10% | 4,643,430 | 155.69M | Jun 29, 2026 |
| Viking Global Investors, L.P. | 5.59% | 3,653,310 | 122.50M | Jun 29, 2026 |
| Eqt Fund Management S.a R.l. | 5.24% | 3,424,609 | 114.83M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.10% | 1,373,193 | 46.04M | Aug 30, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.78% | 1,165,414 | 39.08M | Jul 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.22% | 800,000 | 26.82M | Aug 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 0.99% | 644,591 | 21.61M | Jul 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.61% | 400,000 | 13.41M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.61% | 399,479 | 13.39M | Aug 30, 2026 |